We found although nearly all FGFR2 mutants we selected have the propensity to promote tumorigenesis and metastasis of ICC, not all of the mutants are capable of rendering ICC cells sensitive to targeted therapy. Here, FGFR2 is linked to intrahepatic cholangiocarcinoma.